BridgeBio says Phase 3 FORTIFY data show BBP-418 normalizes HS troponin I in LGMD2I/R9 patients by Month 12

By Public Technologies
  • BridgeBio presented new 12-month exploratory cardiac data from its Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9.
  • Results indicated improvements in heart-injury blood markers, with more patients returning to normal ranges than on placebo.
  • More treated patients showed stable or improved heart pumping function versus placebo, supporting a potential disease-modifying profile.
  • BBP-418 is under FDA Priority Review, with a PDUFA target action date of November 27, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050730PRIMZONEFULLFEED9839250) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.